<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303314</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P-9362-6352</org_study_id>
    <secondary_id>IRCT2013102015083N1</secondary_id>
    <secondary_id>CT-P-9362-6352</secondary_id>
    <nct_id>NCT02303314</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study design to examine performance of trigonella foenum-graecum (TFG) in treatment of&#xD;
      non-alcoholic fatty liver disease. Base on inclusion and exclusion criteria, 50 patients&#xD;
      select and then randomize into intervention and control groups. Two group use capsules which&#xD;
      contain TFG or placebo, respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study design to examine performance of trigonella foenum-graecum in treatment of&#xD;
      non-alcoholic fatty liver disease. Patients 18-70 year old with the levels of ALT and AST&#xD;
      greater than 1.5 and less than 10 times normal level, and ultrasound evidence confirm fatty&#xD;
      liver disease include in study. Patients with alcohol consumption, other liver disease and&#xD;
      taking medications that cause liver injury, exclude. Base on inclusion and exclusion&#xD;
      criteria, 50 patients select and then randomize into intervention and control groups. Control&#xD;
      group, in addition to diet and exercise recommendations take placebo capsules for 3 months.&#xD;
      Intervention group, in addition to diet and exercise recommendations, use capsules containing&#xD;
      hydro-alcoholic extract of fenugreek 1g/d for 3 months. At baseline and 6 and 12 weeks after&#xD;
      intervention, the investigators measure FBS, insulin, insulin resistance, Albumin, Aspartate&#xD;
      transaminase, Alanine Aminotransferase, Alkaline phosphatase, Total bilirubin, Direct&#xD;
      bilirubin, HbA1c, total cholesterol, LDL, HDL, TG, High sensitivity C reactive protein and&#xD;
      Creatinine. At baseline and 12 weeks after intervention fibroscan perform to evaluate the&#xD;
      amount of fat in liver. In order to decrease bias, patient, physician who performs fibroscan&#xD;
      and the person analyzing the data are blind to group drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver stiffness change</measure>
    <time_frame>At baseline and 12 weeks after intervention</time_frame>
    <description>Assessment by Fibroscan</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Drug: Trigonella Foenum-graecum</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>in this group patients use Trigonella Foenum-graecum seed extract twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>in this group patients use placebo twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trigonella Foenum-graecum Seed Extract</intervention_name>
    <arm_group_label>Drug: Trigonella Foenum-graecum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Placebo</intervention_name>
    <arm_group_label>Drug: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  The level of ALT and AST greater than 1.5 and less than 10 times normal level&#xD;
&#xD;
          -  Ultrasound evidence confirm fatty liver disease; age between 18-70 years old&#xD;
&#xD;
          -  Negative pregnancy test for women in reproductive age (up to two weeks prior to the&#xD;
             study)&#xD;
&#xD;
          -  Negative for hepatitis B and C&#xD;
&#xD;
          -  BMI: 18.5 to 40&#xD;
&#xD;
          -  Sign the consent form.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of more than one unit of alcohol consumption (one value for the Spirits&#xD;
             (vodka; whiskey)&#xD;
&#xD;
          -  Wine and Beer are respectively 30-45 cc; 120-150 cc and 360 cc.)&#xD;
&#xD;
          -  Fatty liver controller medications&#xD;
&#xD;
          -  Glucose lowering drugs&#xD;
&#xD;
          -  Cholesterol lowering drugs&#xD;
&#xD;
          -  Hypotensive drugs&#xD;
&#xD;
          -  Consumption of vitamin E&#xD;
&#xD;
          -  Taking coenzyme Q10&#xD;
&#xD;
          -  Administration of corticosteroids &amp; glucocorticoids&#xD;
&#xD;
          -  Thyroxin administration&#xD;
&#xD;
          -  Administration of drugs that cause fatty liver&#xD;
&#xD;
          -  Diabetes (type 1 and 2)&#xD;
&#xD;
          -  History of cancer in the past&#xD;
&#xD;
          -  Hepatocellular carcinoma&#xD;
&#xD;
          -  Renal failure (creatinine&gt; 1.5 x ULN)&#xD;
&#xD;
          -  Chronic pancreatitis&#xD;
&#xD;
          -  Cirrhosis&#xD;
&#xD;
          -  Uncontrolled hypertension (above 180 mm Hg systolic blood pressure); heart disease&#xD;
&#xD;
          -  Autoimmune hepatitis&#xD;
&#xD;
          -  Primary biliary cirrhosis&#xD;
&#xD;
          -  Primary sclerosing cholangitis (alkaline phosphatase levels greater than 3 times&#xD;
             normal)&#xD;
&#xD;
          -  Wilson's disease&#xD;
&#xD;
          -  Alpha-1 antitrypsin deficiency and coronary artery disease&#xD;
&#xD;
          -  Symptoms of hypothyroidism&#xD;
&#xD;
          -  Hyperthyroidism&#xD;
&#xD;
          -  Disorders of the hypothalamic - pituitary&#xD;
&#xD;
          -  Liver transplantation&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Those who cannot use contraceptives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seyed Alireza Taghavi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Amir Hossein Babaei</investigator_full_name>
    <investigator_title>Students of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

